VEA
RAPT

Virtus ETF Advisers’s RAPT Therapeutics RAPT Stock Holding History

Virtus ETF Advisers’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-560
Closed -$40.2K – 476
2024
Q1 		$40.2K Sell
560
-38
-6% -$5.28K 0.02% 420
2023
Q4 		$119K Buy
598
+12
+2% +$1.49K 0.08% 322
2023
Q3 		$78K Sell
586
-58
-9% -$9.47K 0.05% 365
2023
Q2 		$96.4K Sell
644
-44
-6% -$6.85K 0.06% 402
2023
Q1 		$101K Sell
688
-265
-28% -$53.6K 0.06% 336
2022
Q4 		$151K Buy
953
+76
+9% +$12.2K 0.08% 343
2022
Q3 		$169K Buy
877
+6
+0.7% +$1.14K 0.07% 337
2022
Q2 		$127K Buy
871
+236
+37% +$31.5K 0.05% 364
2022
Q1 		$112K Sell
635
-39
-6% -$7.37K 0.05% 284
2021
Q4 		$198K Buy
674
+10
+2% +$2.67K 0.07% 211
2021
Q3 		$165K Sell
664
-35
-5% -$9.25K 0.07% 319
2021
Q2 		$178K Sell
699
-849
-55% -$159K 0.07% 387
2021
Q1 		$275K Buy
1,548
+29
+2% +$4.78K 0.12% 260
2020
Q4 		$240K Sell
1,519
-271
-15% -$58.9K 0.1% 325
2020
Q3 		$461K Sell
1,790
-244
-12% -$54.2K 0.24% 145
2020
Q2 		$472K Buy
+2,034
New +$315K 0.22% 157

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Virtus ETF Advisers's RAPT Position: Q2 2024 in Review

Virtus ETF Advisers sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 560 shares — an estimated $40.2K sold.

Virtus ETF Advisers first reported a position in RAPT in Q2 2020 and held it in 16 quarters. The position peaked at $472K in Q2 2020. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Virtus ETF Advisers reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 560 RAPT Therapeutics shares in Q2 2024, an estimated $40.2K.
  • Virtus ETF Advisers first reported a position in RAPT Therapeutics in Q2 2020 and held it in 16 quarters.
  • Virtus ETF Advisers's RAPT Therapeutics position peaked at $472K in Q2 2020.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.